Daily Cosmetic Research Analysis
Three impactful studies span pediatric dermatology, cosmetic safety analytics, and orthodontic oral health. A phase 3 RCT shows ruxolitinib cream improves pediatric atopic dermatitis; a green analytical workflow detects fluorescent whitening agent migration into cosmetics and even blood/urine; and a triple-blind RCT finds propolis mouthwash outperforms fluoride and probiotics in reducing Streptococcus mutans and oxidative stress during orthodontic treatment.
Summary
Three impactful studies span pediatric dermatology, cosmetic safety analytics, and orthodontic oral health. A phase 3 RCT shows ruxolitinib cream improves pediatric atopic dermatitis; a green analytical workflow detects fluorescent whitening agent migration into cosmetics and even blood/urine; and a triple-blind RCT finds propolis mouthwash outperforms fluoride and probiotics in reducing Streptococcus mutans and oxidative stress during orthodontic treatment.
Research Themes
- Topical JAK inhibition for pediatric atopic dermatitis
- Green analytical chemistry for cosmetic and sanitary product safety
- Adjunctive oral hygiene strategies during orthodontic treatment
Selected Articles
1. Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study.
In 330 children with mild-to-moderate atopic dermatitis, ruxolitinib cream (0.75% and 1.5%) significantly increased IGA treatment success at 8 weeks versus vehicle (36.6%/56.5% vs 10.8%). Itch and quality of life improved, and safety was consistent with adolescent/adult data.
Impact: This is a well-powered, double-blind phase 3 RCT extending topical JAK inhibition to children, demonstrating clinically meaningful efficacy and tolerability.
Clinical Implications: Ruxolitinib cream can be considered a nonsteroidal option for children aged 2–11 years with mild-to-moderate atopic dermatitis, though longer-term safety and head-to-head comparisons with topical steroids/calcineurin inhibitors are needed.
Key Findings
- At week 8, IGA treatment success was 36.6% (0.75%) and 56.5% (1.5%) vs 10.8% with vehicle (P = .0001 and P < .0001).
- Improvements were observed in itch and quality of life measures.
- Safety profile in children was consistent with that in adolescents and adults.
Methodological Strengths
- Phase 3 randomized double-blind design with adequate sample size (N=330)
- Prespecified clinician-reported (IGA) and patient-centered outcomes with statistical significance
Limitations
- Enrollment limited to North America, potentially affecting generalizability
- Short treatment duration (8 weeks) without long-term safety data or active comparator
Future Directions: Head-to-head trials versus topical steroids/calcineurin inhibitors and longer-term safety/maintenance studies in diverse populations.
BACKGROUND: Ruxolitinib (Janus kinase 1 and Janus kinase 2 inhibitor) cream demonstrated efficacy and safety in adolescents and adults with mild-to-moderate atopic dermatitis (AD). OBJECTIVE: To evaluate 8-week efficacy and safety of ruxolitinib cream in children with mild-to-moderate AD. METHODS: This phase 3 study (TRuE-AD3; NCT04921969) enrolled children aged 2-11 years with an Investigator's Global Assessment (IGA) score of 2 or 3 and 3% to 20% affected body surface area. Patients were randomized 2:2:1 to twice-daily ruxolitinib cream (0.75% o
2. Flexible natural deep eutectic solvent extraction coupled with precolumn-switching HPLC-FLD to analyze fluorescent whitening agents in diverse sample matrices for migration study.
A NADES (coumarin/thymol)-based extraction coupled to precolumn-switching HPLC-FLD achieved LODs as low as 0.002 μg/L with 88.2–114.4% recoveries across blood, urine, packaging, cosmetics, and simulants. The study revealed, for the first time, migration of FWAs from sanitary products into blood and urine and modeled migration kinetics using a Weibull model.
Impact: Introduces a green, highly sensitive, multi-matrix method that directly informs cosmetic and sanitary product safety by documenting real-world FWA migration into biological fluids.
Clinical Implications: Though not a clinical trial, the method enables surveillance of consumer exposure to FWAs from cosmetics/sanitary products, supporting regulatory risk assessment and safer material selection.
Key Findings
- NADES (coumarin/thymol) with precolumn-switching HPLC-FLD achieved LODs down to 0.002 μg/L and recoveries of 88.2–114.4%.
- Successfully analyzed FWAs across blood, urine, packaging materials, cosmetics, and simulants without extensive solvent dilution.
- First report of FWAs migrating from sanitary products into blood and urine; Weibull model effectively described migration behavior.
Methodological Strengths
- Green solvent approach (NADES) with automated precolumn-switching preventing column contamination
- Validated across diverse matrices with ultra-low LODs and high recoveries; applied to real positive samples
Limitations
- Analytical study without direct linkage to health outcomes or population-level exposure quantification
- Sample numbers and representativeness across product categories and geographies are not detailed
Future Directions: Integrate this workflow into regulatory monitoring programs and couple with biomonitoring/epidemiology to quantify exposure–response relationships.
This study proposes a novel analytical approach coupling of natural deep eutectic solvent (NADES) extraction with a precolumn-switching high-performance liquid chromatography with fluorescence detection (HPLC-FLD) system for analyzing fluorescent whitening agents (FWAs) in diverse sample matrices. NADES (coumarin/thymol) provide a green alternative to conventional solvents. The automated precolumn-switching strategy overcomes the compatibility issues between DES and HPLC, preventing column contaminatio
3. Comparative evaluation of propolis, fluoride and probiotic mouthwashes on streptococcus mutans and oxidative stress in fixed orthodontic patients: A triple-blind, randomized controlled trial with 9-month follow-up.
In a triple-blind RCT (n=90), propolis mouthwash achieved the largest 9-month reductions in Streptococcus mutans (from 4.35±0.45 to 0.89±0.06 log10 CFU/mL) and salivary 8‑OHdG (3.8±0.8 to 0.32±0.14 ng/mL), outperforming fluoride and probiotic formulations. Compliance was high and monitoring used qPCR and ELISA.
Impact: Provides randomized, triple-blind evidence for a non-fluoride adjunct that may improve microbial and oxidative stress profiles during orthodontic treatment.
Clinical Implications: Propolis mouthwash may be considered as an adjunct to standard oral hygiene in fixed orthodontic patients, with potential to reduce demineralization risk; standardization of formulations and broader multicenter trials are needed.
Key Findings
- Propolis reduced S. mutans from 4.35±0.45 to 0.89±0.06 log10 CFU/mL at 9 months (P<0.001), greater than fluoride and probiotics.
- Salivary 8‑OHdG decreased most with propolis (3.8±0.8 to 0.32±0.14 ng/mL; P<0.001) vs fluoride and probiotics.
- High compliance with monitoring via mobile app, interviews, and 24-hour dietary recalls.
Methodological Strengths
- Triple-blind randomized controlled design with 9-month follow-up
- Objective quantification using qPCR for S. mutans and ELISA for 8‑OHdG
Limitations
- Surrogate outcomes without direct caries/white-spot lesion endpoints
- Single study with n=90; formulation components (standardized extract and essential oils) may limit generalizability
Future Directions: Multicenter trials assessing clinical endpoints (white spot lesions/caries) and head-to-head comparisons with chlorhexidine and other antiseptics; dose–response and formulation standardization.
BACKGROUND: Fixed orthodontic appliances increase the risk of enamel demineralization due to plaque accumulation. While fluoride mouthwash is well established, propolis and probiotic formulations are emerging alternatives with antimicrobial and anti-inflammatory potential. AIM: To compare the effects of propolis, fluoride, and probiotic mouthwashes on Streptococcus mutans levels and oxidative stress (8-OHdG) in patients undergoing fixed orthodontic treatment. MATERIALS AND METHODS: Of 120 p